Search Results | Blood | American Society of Hematology

1-20 of 52

2 3

Sort by

Sort Order Select

Journal Articles

Clinical features of thrombosis and bleeding in COVID-19

Mari R. Thomas, Marie Scully

Blood (2022) 140 (3): 184–195.

DOI: https://doi.org/10.1182/blood.2021012247

Published: 2022

Journal Articles

Natural history of PF4 antibodies in vaccine-induced immune thrombocytopenia and thrombosis

Brian Craven, William Lester, Sara Boyce, Will Thomas, Angela Kanny, Claire Davies, Sue Pavord, Joannes Hermans, Michael Makris, Emily Bart-Smith, Sarah Arnott, Beverley J. Hunt, Pavel Chudakou, Anthony Calvert, Deepak Singh, Marie Scully

Blood (2022) 139 (16): 2553–2560.

DOI: https://doi.org/10.1182/blood.2021014684

Published: 2022

Includes: Supplemental data

Journal Articles

Long-Term Safety and Efficacy of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura (aTTP): The Post-HERCULES Study

Marie Scully, Javier de la Rubia, Katerina Pavenski, Ara Metjian, Paul Knoebl, Flora Peyvandi, Spero Cataland, Paul Coppo, Johanna A. Kremer Hovinga Strebel, Jessica Minkue Mi Edou, Rui de Passos Sousa, Filip Callewaert, Sriya Gunawardena, Julie Lin

Blood (2021) 138 (Supplement 1): 2080.

DOI: https://doi.org/10.1182/blood-2021-148839

Published: 2021

Journal Articles

Congenital TTP: next stop, acuity and therapy

Marie Scully

Blood (2021) 137 (25): 3469–3471.

DOI: https://doi.org/10.1182/blood.2021011265

Published: 2021

Journal Articles

Redefining outcomes in immune TTP: an international working group consensus report

Adam Cuker, Spero R. Cataland, Paul Coppo, Javier de la Rubia, Kenneth D. Friedman, James N. George, Paul N. Knoebl, Johanna A. Kremer Hovinga, Bernhard Lӓmmle, Masanori Matsumoto, Katerina Pavenski, Flora Peyvandi, Kazuya Sakai, Ravi Sarode, Mari R. Thomas, Yoshiaki Tomiyama, Agnès Veyradier, John-Paul Westwood, Marie Scully

Blood (2021) 137 (14): 1855–1861.

DOI: https://doi.org/10.1182/blood.2020009150

Published: 2021

Includes: Supplemental data

Journal Articles

Real-world experience with caplacizumab in the management of acute TTP

Blood (2021) 137 (13): 1731–1740.

DOI: https://doi.org/10.1182/blood.2020007599

Published: 2021

Includes: Supplemental data

Journal Articles

Plasma Exchange for COVID-19 Thrombo-Inflammatory Disease

Mari Thomas, Nishkantha Arulkumaran, David Brearley, Ferras Alwan, Deepak Singh, Michael P Lunn, Anna Welch, Samuel Clark, Eamon Raith, Ugan Reddy, Ryan Low, David Leverett, Mervyn Singer, Marie Scully, MD

Blood (2020) 136 (Supplement 1): 27.

DOI: https://doi.org/10.1182/blood-2020-138851

Published: 2020

Journal Articles

Factors Influencing Time from Initial Presentation to Start of Plasma Exchange (PEX) in Patients with Acute Thrombotic Thrombocytopenic Purpura (TTP)

Rory McCulloch, FRCPath, MRCP, MBBS, Tom Bull, MBBS,FRCPath,MRCP, Phillip LR Nicolson, MA, MBBChir, MRCP, Rebecca J Shaw, MRCP, Zara Sayar, MD FRCPath, MRCP, Alexander Langridge, Michala Pettitt, PhD, Rita Perry, David Tucker, MD, Marie Scully, MD, HaemSTAR Collaborators. (# joint first authors)

Blood (2020) 136 (Supplement 1): 9–10.

DOI: https://doi.org/10.1182/blood-2020-133371

Published: 2020

Journal Articles

Long-Term Safety and Efficacy of Sutimlimab in Patients with Chronic Immune Thrombocytopenia

Catherine M. Broome, Alexander Röth, MD, David J. Kuter, MD, Marie Scully, MD, Roy Smith, Jennifer Wang, Xiaoyu Jiang, Caroline Reuter, Ahmed Daak, William Hobbs

Blood (2020) 136 (Supplement 1): 14–15.

DOI: https://doi.org/10.1182/blood-2020-139663

Published: 2020

Journal Articles

Increased Activated Circulating T Follicular Helper Cells and Changes in B Cell Subsets in Immune TTP (iTTP) and in Response to Rituximab Treatment

Jin-Sup Shin, Geraldine Cambridge, PhD, Yanping Guo, DPhil, Marie Scully, MD, Mari Thomas

Blood (2020) 136 (Supplement 1): 23–24.

DOI: https://doi.org/10.1182/blood-2020-140337

Published: 2020

Journal Articles

Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group

Blood (2020) 136 (19): 2103–2117.

DOI: https://doi.org/10.1182/blood.2020005221

Published: 2020

Includes: Supplemental data

Journal Articles

TTP: an open and shut (closed) case

Marie Scully

Blood (2020) 136 (3): 265–266.

DOI: https://doi.org/10.1182/blood.2020006444

Published: 2020

Journal Articles

Inhibition of the Classical Pathway of Complement with Sutimlimab in Chronic Immune Thrombocytopenic Purpura Patients without Adequate Response to Two or More Prior Therapies

Catherine M Broome, MD, Alexander Röth, MD PhD, David J. Kuter, Marie Scully, Roy Smith, Jennifer Wang, Caroline Reuter, William Hobbs

Blood (2019) 134 (Supplement_1): 898.

DOI: https://doi.org/10.1182/blood-2019-122210

Published: 2019

Journal Articles

Safety of Caplacizumab in Patients Without Documented Severe ADAMTS13 Deficiency During the HERCULES Study

Javier De La Rubia, Flora Peyvandi, MD PhD, Marie Scully, Spero Cataland, MD, Paul Coppo, MD PhD, Johanna A. Kremer Hovinga, MD Prof, Paul Knoebl, MD, Ara Metjian, MD, Katerina Pavenski, MD, Hilde De Winter, MD, Rui de Passos Sousa, Filip Callewaert

Blood (2019) 134 (Supplement_1): 1093.

DOI: https://doi.org/10.1182/blood-2019-124004

Published: 2019

Journal Articles

Discordance between Free C5 and CH50 Complement Assays in Measuring Complement C5 Inhibition in Patients with aHUS Treated with Ravulizumab

Spero Cataland, MD, Gema Ariceta, Peter Chen, Bradley Dixon, Katherine Garlo, Laurence Greenbaum, MD PhD, Eric Rondeau, Marie Scully, Stephan Ortiz, RPh, PhD

Blood (2019) 134 (Supplement_1): 1099.

DOI: https://doi.org/10.1182/blood-2019-122421

Published: 2019

Journal Articles

A Pilot Study on Biomarkers of Vascular Injury in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura

Camila Masias, MDMPH, Rawan Tarawneh, MD, Haiwa Wu, Krista Carter, Shangbin Yang, PhD, Alcinda Flowers, MD, Marie Scully, Spero Cataland, MD

Blood (2019) 134 (Supplement_1): 2377.

DOI: https://doi.org/10.1182/blood-2019-130369

Published: 2019

Journal Articles

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression Regimen

Katerina Pavenski, MD, Paul Knoebl, MD, Marie Scully, Johanna A. Kremer Hovinga, MD Prof, Paul Coppo, MD PhD, Flora Peyvandi, MD PhD, Spero Cataland, MD, Ara Metjian, MD, Javier De La Rubia, Hilde De Winter, MD, Rui de Passos Sousa, Filip Callewaert

Blood (2019) 134 (Supplement_1): 2365.

DOI: https://doi.org/10.1182/blood-2019-123126

Published: 2019

Journal Articles

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Baseline Disease Severity

Paul Coppo, MD PhD, Spero Cataland, MD, Flora Peyvandi, MD PhD, Paul Knoebl, MD, Marie Scully, Johanna A. Kremer Hovinga, MD Prof, Ara Metjian, MD, Javier De La Rubia, Katerina Pavenski, MD, Hilde De Winter, MD, Rui de Passos Sousa, Filip Callewaert

Blood (2019) 134 (Supplement_1): 2366.

DOI: https://doi.org/10.1182/blood-2019-123720

Published: 2019

Journal Articles

Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies

Spero Cataland, MD, Marie Scully, Flora Peyvandi, MD PhD, Paul Knoebl, MD, Johanna A. Kremer Hovinga, MD Prof, Paul Coppo, MD PhD, Ara Metjian, MD, Javier De La Rubia, Katerina Pavenski, MD, Hilde De Winter, MD, Filip Callewaert

Blood (2019) 134 (Supplement_1): 4908.

DOI: https://doi.org/10.1182/blood-2019-123124

Published: 2019

Journal Articles

Characterization and treatment of congenital thrombotic thrombocytopenic purpura

Blood (2019) 133 (15): 1644–1651.

DOI: https://doi.org/10.1182/blood-2018-11-884700

Published: 2019

2 3

NARROW

Clinical features of thrombosis and bleeding in COVID-19

Natural history of PF4 antibodies in vaccine-induced immune thrombocytopenia and thrombosis

Long-Term Safety and Efficacy of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura (aTTP): The Post-HERCULES Study

Congenital TTP: next stop, acuity and therapy

Redefining outcomes in immune TTP: an international working group consensus report

Real-world experience with caplacizumab in the management of acute TTP

Plasma Exchange for COVID-19 Thrombo-Inflammatory Disease

Factors Influencing Time from Initial Presentation to Start of Plasma Exchange (PEX) in Patients with Acute Thrombotic Thrombocytopenic Purpura (TTP)

Long-Term Safety and Efficacy of Sutimlimab in Patients with Chronic Immune Thrombocytopenia

Increased Activated Circulating T Follicular Helper Cells and Changes in B Cell Subsets in Immune TTP (iTTP) and in Response to Rituximab Treatment

Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group

TTP: an open and shut (closed) case

Inhibition of the Classical Pathway of Complement with Sutimlimab in Chronic Immune Thrombocytopenic Purpura Patients without Adequate Response to Two or More Prior Therapies

Safety of Caplacizumab in Patients Without Documented Severe ADAMTS13 Deficiency During the HERCULES Study

Discordance between Free C5 and CH50 Complement Assays in Measuring Complement C5 Inhibition in Patients with aHUS Treated with Ravulizumab

A Pilot Study on Biomarkers of Vascular Injury in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression Regimen

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Baseline Disease Severity

Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies

Characterization and treatment of congenital thrombotic thrombocytopenic purpura

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only